PharmiWeb.com - Global Pharma News & Resources
15-Feb-2019

Outlook of Dengue Vaccines Market Status And Ongoing Development Trends Reviewed In New Report

Dengue is a mosquito born disease caused by ‘Aedes Aegypti’ species of female mosquito mostly seen in tropical and subtropical countries. It is a viral infection where human act as reservoir and diseases is transmitted by mosquito to humans. The dengue virus belongs to the flaviviridae family of viruses that cause diseases in humans. There are four serotypes of viruses namely DENV-1, DENV-2, DENV-3 and DENV-4. The plaque reduction neutralization titer (PRNT) assay is diagnostic test used for measuring the immune response to dengue vaccines. WHO emphasizes that dengue vaccine introduction should be a part of a comprehensive dengue control strategy, including a well-executed and sustained vector control, the best evidence-based clinical care for all patients with dengue illness, and dengue surveillance.

Increase in incidence of dengue fever is the key factor driving the demand of dengue vaccines market globally. In addition sudden climatic changes, development of new vaccines such as live-attenuated dengue vaccines, government initiatives, unplanned and uncontrolled urbanization, lack of basic amenities in communities, and poor environmental management are factors that are expected to boost the growth of global dengue vaccines market.

Inadequate cold chain systems for storage of vaccine, standardised diagnostics practice, lack of proper surveillance system and regulatory hurdles in vaccines preparations are the factors hindering the growth of the global dengue vaccine market.

Certain vendors are focusing on introducing dengue vaccines and expanding its portfolio and presence across developing countries in the Asia Pacific region through government support. For example, Sanofi’s ‘dengvaxia’ is the only licensed dengue vaccine worldwide and the company is expanding its presence across Asia Pacific region. In addition, in 2017, Takeda Pharmaceutical Company Ltd announced plans to launch a dengue vaccine in order to cater to preventive measure for dengue disease across the globe. Also, technological approaches, such as virus-vectored and VLP-based vaccines are under evaluation in preclinical studies.

To Get Sample Copy of Report visit @ https://marketresearch.biz/report/dengue-vaccines-market/request-sample/

The global dengue vaccines market report has been segmented on the basis of technology, distribution channel and region. On the basis of region, market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Currently in Asia pacific countries like Brazil, Mexico, Thailand, Singapore and India due to rapid urbanization, limited access to basic services, rapid movement of people and goods, and possibly climate change are the factors driving market for dengue vaccine accounting nearly 70 percent of market revenue.

Key players in the dengue vaccines market include Sanofi Pasteur Inc., Merck & Co., Inc., GlaxoSmithKline plc, Pfizer Inc., Panacea Biotec Limited., Instituto Butantan, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Limited, GeneOne Life Science Inc and Medigen Vaccine Biologics Corporation.

 

Editor Details

Last Updated: 15-Feb-2019